As for the translational and clinical implications, a MAP4K4 inhibitor DMX-5804 reversed the adverse phenomena for AAA formation induced by loss of RhoA in VSMCs, providing a therapeutic potential of this inhibitor for AAA in which RhoA expression and MAP4K4 activity were remarkably decreased. This evidence concerns the gene MAP4K4 and triple-A syndrome.